Table 1.
ECM components | |||||||||
---|---|---|---|---|---|---|---|---|---|
CS | C-6-S | Tenascin-C | Versican | ||||||
Cells | Culture conditions | M | G | M | G | M | G | M | G |
HT-29 | 10% FCS | − | − | − | − | + | + | − | − |
NFCS or 1% FCS | − | − | − | − | + | + | − | − | |
S-CM | − | − | − | − | +++ | ++ | − | − | |
TGF-β | − | − | − | − | +++ | +++ | − | − | |
Caco-2 | 10% FCS | − | − | − | − | − | − | − | − |
NFCS or 1% FCS | − | − | − | − | − | − | − | − | |
S-CM | − | − | − | − | ++ | ++ | − | − | |
TGF-β | − | − | − | − | +++ | +++ | − | − | |
Stromal cells | 10% FCS | + | + | + | + | + | + | + | + |
NFCS or 1% FCS | + | + | + | + | + | + | + | + | |
Caco-2-CM | +++ | ++ | +++ | ++ | +++ | ++ | +++ | ++ | |
Caco-2-CM + anti-TGF-β | + | + | + | + | + | + | + | + | |
HT-29-CM | ++ | ++ | ++ | ++ | + | ++ | ++ | +++ | |
HT-29-CM + anti-TGF-β | + | + | + | + | + | + | + | ++ | |
TGF-β | +++ | +++ | ++ | ++ | +++ | +++ | +++ | ++ | |
PDGF | +++ | +++ | +++ | +++ | + | + | +++ | +++ | |
bEGF | + | + | + | + | + | + | + | + | |
IGF-I | + | + | + | + | + | + | + | + | |
IGF-II | + | + | + | + | + | + | + | + | |
Caco-2 and stromal cells | NFCS or 1% FCS | +++ | +++ | +++ | +++ | +++ | +++ | +++ | ++ |
HT-29 and stromal cells | NFCS or 1% FCS | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ |
FCS, fetal calf serum; NFCS, no fetal calf serum; S-CM, stromal cell-conditioned media; Caco-2-CM, Caco-2 cell-conditioned media; HT-29-CM, HT-29-conditioned media; TGF, transforming growth factor; PDGF, platelet-derived growth factor; bEGF, basic epidermal growth factor; IGF, insulin-like growth factor; M, monolayers on plastic; G, three-dimensional gels; +++, strong reaction; ++, moderate reaction; +, weak reaction; –, negative reaction.